insight grants are expected to respond to the objectives of the insight program.

insight grants support research excellence in the social sciences and humanities. funding is available to both emerging and established scholars for research initiatives of two to five years.

stable support for long-term research initiatives is central to advancing knowledge. it enables scholars to address complex issues about individuals and societies, and to further our collective understanding.

insight grants support research proposed by scholars and judged worthy of funding by their peers and/or other experts. insight grant research initiatives can be undertaken by an individual researcher or a team of researchers working in collaboration.

applicants choose from one of two streams, depending on the amount of funding required. both streams will be adjudicated by the same committees, and will receive the same rigorous level of merit review. the deadlines and application process are identical for both; however, the targeted success rate for stream a is higher than for stream b.

sshrc welcomes applications involving indigenous research, as well as those involving research-creation.

sshrc postdoctoral fellowships are expected to respond to the objectives of the talent program.

these fellowships support the most promising canadian new scholars in the social sciences and humanities, and assist them in establishing a research base at an important time in their research careers.

the purpose of these fellowships is to provide stipendiary support to recent phd graduates who are:

• undertaking original research;
• publishing research findings;
• developing and expanding personal research networks;
• broadening their teaching experience;
• preparing for research-intensive careers within and beyond academia; and
• preparing to become competitive in national research grant competitions.

sshrc postdoctoral fellowship awards are tenable at canadian or foreign universities and research institutions.

sshrc welcomes applications involving indigenous research, as well as those involving research-creation.

the specific objective of this funding opportunity is to:

• create new knowledge through the analysis of existing cohorts, data platforms and/or administrative datasets specific to reproductive, maternal, child, and/or youth health, and in turn improve health outcomes and inform population and public health decision making.

the fy22 rtrp funding opportunity announcements for the following award mechanisms are posted on the grants.gov website. 

funding opportunities-fy21 reconstructive transplant research program, congressionally directed medical research programs (cdmrp) (army.mil)

investigator-initiated research award – preproposal due july 27, 2022

independent investigators at all academic levels (or equivalent)

• ·      supports studies with the potential to make an important contribution to the reconstructive transplant research field, patient care, and/or quality of life.
• ·      pre-application submission is required; application submission is by invitation only.
• ·      applications must address at least one of the fy22 rtrp investigator-initiated research award focus areas.
• ·      preliminary and/or published data relevant to reconstructive transplantation and support the rationale for the proposal research are required.
• ·      multiple principal investigator (pi) option:
• ·      supports synergistic partnerships among two to four investigators collaborating on a single application.

single pi:

• ·        maximum funding of $1 million (m) for total costs (direct plus indirect costs).
  • ·        maximum period of performance is 3 years.

multiple pi option:

• ·        maximum total funding of $1.5m for total costs (direct plus indirect costs).
• ·        maximum period of performance is 3 years.

advanced technology development award – preproposal due july 27, 2022

independent investigators at all academic levels (or equivalent)

• ·      supports research critical for the translation of promising preclinical findings into products focused on reconstructive transplantation.
• ·      pre-application submission is required; application submission is by invitation only.
• ·      applications must address at least one of the fy22 rtrp advanced technology development award focus areas.
• ·      preproposal is required; full application submission is by invitation only.
• ·      preliminary and/or published data relevant to reconstructive transplantation and support for the rationale for the proposed research are required.
• ·      multiple principal investigator (pi) option:

supports synergistic partnerships among two to four investigators collaborating on a single application; multi-institutional collaborations are encouraged.

single pi:

• ·        maximum funding of $1m for total costs (direct plus indirect costs).
  • ·        maximum period of performance is 3 years.

multiple pi option:

• ·        maximum total funding of $1.5m for total costs (direct plus indirect costs).
• maximum period of performance is 3 years.

 for more information, please contact jill sherman, international research facilitator, at intl.research@lakeheadu.ca.

the fy22 rtrp funding opportunity announcements for the following award mechanisms are posted on the grants.gov website.

funding opportunities-fy21 reconstructive transplant research program, congressionally directed medical research programs (cdmrp) (army.mil)

concept award – letter of intent due september 28, 2022

independent investigators at or above the level of postdoctoral fellow (or equivalent)

• ·      supports the exploration of a highly innovative new concept or untested theory that addresses an important problem relevant to reconstructive transplantation.
• ·      applications must address at least one of the fy22 rtrp concept award focus areas.
• ·      preliminary data are not allowed.
• ·      reviewers at both tiers of review will be blinded to the identities of the pi, collaborators, and their organizations.
• ·      maximum funding of $200,000 for total costs (direct plus indirect costs).
• ·      maximum period of performance is 18 months.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final funding opportunity announcements available for downloading from the grants.gov website.  the application package containing the required forms for each award mechanism can be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the rtrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

for more information, please contact jill sherman, international research facilitator, at int.research@lakeheadu.ca.

the fy22 defense appropriations act is anticipated to provide funding for the kcrp to support research of exceptional scientific merit in the area of kidney cancer.  the managing agent for the anticipated program announcements/funding opportunities is the cdmrp at the u.s. army medical research and development command (usamrdc).

the fy22 kcrp funding opportunity announcements for the following award mechanisms are posted on the grants.gov website. 

applications submitted to the fy22 kcrp must address one or more of the following focus areas:

• conduct basic biology research to better understand etiology and cancer progression, metastatic disease, refractory disease and therapeutic resistance, genetic and environmental risk factors and the prevention of kidney cancer.
• define the biology of rare kidney cancers and develop treatments to improve outcomes and reduce death.
• identify and develop new strategies for screening, early-stage detection, accurate diagnosis and prognosis prediction of kidney cancers, with examples including biomarkers and imaging.
• develop novel therapeutic strategies for the treatment of kidney cancer, such as novel drug targets, therapeutic modalities and agents, treatment combinations, and drug delivery systems.
• identify and implement strategies to improve the quality of life and survivorship for patients.
• identify and implement strategies to mitigate health disparities, such as access to healthcare, social and cultural factors, environmental factors, and biological contributors.
• support preparation and development of the next generation of kidney cancer researchers, or cultivate collaborations in kidney cancer research or patient care in alignment with the kcrp overarching strategic goals.

funding opportunities - fy22 kidney cancer research program, congressionally directed medical research programs (cdmrp) (army.mil)

academy of kidney cancer scholars – early-career investigator award – letter of intent september 29, 2022

must be within 4 years of last postdoctoral research position (ph.d.) or clinical fellowship (m.d.), or equivalent, as of full application submission deadline.

letter attesting to eligibility required.

• ·        supports the addition of new early-career scholars to the unique, interactive virtual academy providing intensive mentoring, national networking, and a peer group for junior faculty.
• ·        early-career scholars whose ability to commit to conducting kidney cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.
• ·        a designated mentor who is an experienced kidney cancer researcher with a record of kidney cancer funding is required.
• ·        the designated mentor not required to be at the same institution as the early-career scholar.
• ·        preliminary data required.
• ·        clinical trials are not allowed.
• ·        maximum funding of $725,000 for direct costs (plus indirect costs).
• ·        maximum period of performance 4 years.
• ·        indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

nurse-initiated research award – letter of intent due september 29, 2022

must have a registered nurse license and/or a master’s or doctoral degree in nursing.

• ·        supports nursing research pertaining to kidney cancer patient care.
• ·        clinical trials are not allowed; correlative studies to clinical trials are allowed. qualified collaboration option: leveraging of existing infrastructure of a federally funded partnership/consortium is encouraged.
• ·        •maximum funding of $300,000 for direct costs (plus indirect costs).
• ·        •maximum period of performance is 2 years.
• ·        •indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

clinical trial award modified for fy22 – letter of intent due september 29, 2022

independent investigators at all levels.

•                  supports projects ranging from small proof-of-concept trials (e.g., pilot, first in human, phase 0) to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.

•                  clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies.

•                  investigational new drug (ind) or investigational device exemption (ide) application, if applicable, must be submitted to the u.s. department of food and drug administration (fda) by the time of application submission.

•                  documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study must be provided.

•                  clinical trials are expected to begin no later than 12 months after the award date, or 18 months after the award date for fda-regulated studies.

•                  qualified collaboration option: leveraging of existing infrastructure of a federally funded partnership/consortium is encouraged.

•                  maximum funding of

• ·        $1,500,000 for direct costs (plus indirect costs).

•                  maximum period of performance is 4 years.

•                  indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

• ·        cell therapy focus option:

•                  maximum funding of

• ·        $2,000,000 for direct costs (plus indirect costs).

•                  maximum period of performance is 4 years.

•                  indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final funding opportunity announcements that will be available for downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the kcrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk

301-682-5507
help@ebrap.org

for more information, please contact jill sherman, international research facilitator, at intl.research@lakeheadu.ca.

the genomic applications partnership program (gapp) funds downstream research and development (r&d) projects that address real-world opportunities and challenges defined by “receptor” organizations such as industry, government, or not-for-profit entities. these organizations should have the expertise, resources and commitment to commercialize or implement the project’s outcomes. projects must be active collaborations between the receptor organization (canadian or international) and a canadian academic researcher. both must play an integral role in the project. these projects are co-funded by receptors and other stakeholders and must have the potential to generate significant social and/or economic benefits for canada.

the forest sector investment and innovation program provides funding for strategic investments in the forest sector that:

• enhance competitiveness
• support new market access
• provide benefits to ontario’s broader forest sector
• strengthen regional economies

support is available under two project categories:

• business projects
• collaboration projects

the cancer therapeutics innovation pipeline (ctip) program was established to capitalize on ontario’s expertise in cancer biology and drug discovery. its aim is to create a pipeline of validated cancer targets and first-in-class or best-in-class, novel, selective lead molecules (small molecules or biologics) that will attract partnerships and/or investment for further preclinical and clinical development. to generate a sustainable pipeline, ctip will support projects that aim to provide increasing evidence of target validation and disease association using data from knowledge bases, functional assays, and drug screening in relevant in vitro and in vivo models of the cancer type of interest.

the r&d partnership fund - electric vehicle (ev) – stream 2 program supports projects related to the development and demonstration of technologies in electric vehicles (ev) and battery manufacturing technologies in the following priority areas:

• mass light vehicles, such as cars, trucks and vans
• heavy duty vehicles, including commercial vehicles, trucks, buses, recreational vehicles (rvs), and others used for goods movement
• charging infrastructure
• intelligent transportation systems (its)
• transit-supportive systems and vehicles